2024

article thumbnail

2024 predictions: Experts comment on AI, ML and automation

Drug Discovery World

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in the sector. Updesh Dosanjh, Practice Leader for Pharmacovigilance Technology Solutions, IQVIA “In 2024, the traditional pain points of the pharmacovigilance (PV) space will not disappear.

article thumbnail

Early Impact Of The Inflation Reduction Act On Drug Discovery

Forbes: Drug Truths

There is another aspect of this provision of the IRA that is starting to be felt – "the small molecule penalty"

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists link certain gut bacteria to lower heart disease risk

Broad Institute

Scientists link certain gut bacteria to lower heart disease risk By Allessandra DiCorato April 2, 2024 Breadcrumb Home Scientists link certain gut bacteria to lower heart disease risk Study finds several species of cholesterol-metabolizing bacteria in people with lower cholesterol levels. By Allessandra DiCorato April 2, 2024 Credit: Ahmed Mohamed Rod-shaped Oscillibacter sp. bacteria take up fluorescently labeled cholesterol (here shown in green).

Disease 145
article thumbnail

Psychiatry drugs finally have pharma’s attention. Can they keep it?

BioPharma Drive: Drug Pricing

Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

Treatment 137
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA Warns of Toxic Lead in Cinnamon Products

Drugs.com

WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead. The FDA urged folks to throw away and not buy the following brands of.

FDA 145
article thumbnail

8-hour time-restricted eating linked to a 91% higher risk of cardiovascular death

Science Daily: Pharmacology News

A study of over 20,000 adults found that those who followed an 8-hour time-restricted eating schedule, a type of intermittent fasting, had a 91% higher risk of death from cardiovascular disease.

Disease 141

More Trending

article thumbnail

The science of ageing and restoring healthspan

Drug Target Review

What is “healthspan” and how does it relate to Life Bioscience’s mission? It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. If we take into consideration the timeframe of our lives, our “healthspan” is defined as the number of healthy years we live, which is different than our lifespan, the number of years of life.

Science 145
article thumbnail

Optimizing OpenFold Training for Drug Discovery

Nvidia Developer: Drug Discovery

Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep. Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep learning–based computational methods have been emerging and have shown promising results.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst of enthusiasm for a sector that has seen its challenges in 2022 and 2023 but also some green shoots. 2023 was a stellar year for M&A, comeback stories, burgeoning “hot” spaces, and for re-learning the basics of belt-tightening and careful capital allocation.

article thumbnail

Vector Space Biosciences: Leading Innovation in Space Medicine with AI

DrugBank

Space biosciences are on the verge of becoming one of the largest total addressable markets to ever exist, opening up vast opportunities for economic growth and scientific discovery.  In the realm of space exploration, one critical yet often overlooked aspect is the impact of space conditions on human health. The goal of sending humans to space for increasingly longer periods of time is contingent on our ability to ensure astronauts' health.

DNA 121
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

The killer instinct: Using investigational natural killer therapy to treat Alzheimer’s

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Paul Song , MD, NKGen and Dr Vince DeOrchis , clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease.

Therapies 306
article thumbnail

How long do clinical trials take?

Antidote

Before it is released onto the market, the development of any new drug or medical device must undergo rigorous testing , part of which involves clinical trials. Clinical trials are integral to making sure that any new therapy is both safe and effective for individuals, and volunteers are a vital part of the process.

article thumbnail

Scientists generate new targeted protein degradation system that tunes a cell’s own proteins

Broad Institute

Scientists generate new targeted protein degradation system that tunes a cell’s own proteins By Leah Eisenstadt March 14, 2024 Breadcrumb Home Scientists generate new targeted protein degradation system that tunes a cell’s own proteins Researchers have engineered a compact degron tag that can be precisely edited into a cell’s genome, enabling scientists to trigger the rapid breakdown of native target proteins.

article thumbnail

CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease

BioPharma Drive: Drug Pricing

Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.

Therapies 141
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

U.S. Mpox Cases Rising Again as Vaccinations Lag

Drugs.com

THURSDAY, March 28, 2024 -- Mpox cases are climbing again in the United States, with the number of reported infections now twice as high as they were at this time last year, new government data shows.In response, public health experts have raised.

Vaccine 134
article thumbnail

Robot, can you say 'cheese'?

Science Daily: Pharmacology News

What would you do if you walked up to a robot with a human-like head and it smiled at you first? You'd likely smile back and perhaps feel the two of you were genuinely interacting. But how does a robot know how to do this? Or a better question, how does it know to get you to smile back?

140
140
article thumbnail

Addgene is Stopping Use of X (formerly Twitter)

addgene Blog

Addgene is announcing we have chosen to stop all activity on X, formerly Twitter. If you are interested in engaging with us on social media, you can find us on Bluesky: @addgene.bsky.social; or @addgene on Instagram, TikTok, Facebook, and LinkedIn. We are also exploring other social media platforms with active scientific communities and welcome suggestions in the comments.

129
129
article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. 1 Surprisingly, however, less than one percent of the natural world’s chemical composition has been identified or studied by scientists. While plant-derived molecules (phytochemicals) have long played an essential role in drug discovery due to their diverse biological activities and chemical properties, the reliance on time-consuming and expensive screening techniques

article thumbnail

Achieving New Heights in Healthcare Marketing With Salesforce Marketing Cloud Personalization

Perficient: Drug Development

In December 2022, the Department of Health and Human Services released a bulletin announcing additional compliance requirements for healthcare marketers when it comes to third-party trackers. The guidance lays forth expectations for how healthcare organizations collect data on activities that take place on their website and mobile apps. So, what’s the problem?

Marketing 122
article thumbnail

Deliberate Dysentery

Codon

Introduction The intentional infection of human beings with pathogens under study has been going on for centuries. In 1796, an English physician named Edward Jenner inoculated an 8-year-old boy against smallpox with cowpox lesions he retrieved from the hands of a dairymaid. Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying

Vaccine 124
article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)

Practical Cheminformatics

Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful.

article thumbnail

DDW Winter 2023/2024

Drug Discovery World

The DDW Winter issue asks whether AI can deliver better immunotherapies for cancer and includes expert predictions on what to expect from the sector in 2024, alongside a supplement looking at SLAS2024 and an exclusive guide exploring therapeutic antibodies. DDW Winter 2023/2024 The post DDW Winter 2023/2024 appeared first on Drug Discovery World (DDW).

Drugs 312
article thumbnail

Antidote anecdotes: A conversation with an MS care partner

Antidote

MS is a chronic disease that is estimated to impact over a million Americans. The condition causes damage to the body’s central nervous system, leading to numbness, memory problems, sight issues, and difficulties with coordination.

Disease 116
article thumbnail

Spatial study of lung cancer reveals immune markers of response to immunotherapy

Broad Institute

Spatial study of lung cancer reveals immune markers of response to immunotherapy By Corie Lok March 20, 2024 Breadcrumb Home Spatial study of lung cancer reveals immune markers of response to immunotherapy Researchers visualize how immune cells are spatially organized within tumors and show that certain immune “hubs” are linked to better treatment responses.

article thumbnail

Amylyx ALS drug fails crucial study, putting company’s future in doubt

BioPharma Drive: Drug Pricing

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Marketing 137
article thumbnail

COVID Can Threaten Sickle Cell Patients, But Too Few Are Vaccinated

Drugs.com

FRIDAY, Jan. 12, 2024 -- Sickle cell disease is one of many chronic health conditions that dramatically increases the risk of hospitalization and death in people infected by COVID-19.Unfortunately, folks with sickle cell disease are much less.

Vaccine 141
article thumbnail

Ice cores provide first documentation of rapid Antarctic ice loss in the past

Science Daily: Pharmacology News

Researchers have uncovered the first direct evidence that the West Antarctic Ice Sheet shrunk suddenly and dramatically at the end of the Last Ice Age, around eight thousand years ago. The evidence, contained within an ice core, shows that in one location the ice sheet thinned by 450 meters -- that's more than the height of the Empire State Building -- in just under 200 years.

Research 145
article thumbnail

Finding the Right Fit—Is Your Respirator “The One”?

NIOSH Science Blog: Drugs

Finding the right fit is one of the most important parts of a relationship. You don’t just grab any old fish from the sea that swims by and hope for the best. First, it’s necessary to test the waters and ensure you’re simpatico before settling on a partner. It’s Valentine’s Day, and yes, this advice could apply to your romantic life, but we also love to use today to show our love of respirators and we love to play matchmaker on your behalf as well.

120
120
article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. It is now more than a decade since Francesco De Rubertis, together with Kevin Johnson and Michele Olier, coined the term “asset-centric” investing to describe the approach to portfolio creation that still underpins the strategy at Medicxi.

article thumbnail

Accelerating Drug Discovery at Receptor.AI with NVIDIA BioNeMo Cloud APIs

Nvidia Developer: Drug Discovery

The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. This traditionally. The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. This traditionally long and expensive process has been radically improved by AI techniques like deep learning, empowered by the rise of accelerated computing.

Drugs 134
article thumbnail

Scaling Phage Therapy

Codon

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Read it on our website here. Illustration by David S. Goodsell, RCSB Protein Data Bank and Scripps Research. doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of u

Therapies 135
article thumbnail

AI in Drug Discovery 2023 - A Highly Opinionated Literature Review (Part I)

Practical Cheminformatics

Here’s the first part of my review of some interesting machine learning (ML) papers I read in 2023. As with the previous editions , this shouldn’t be considered a comprehensive review. The papers covered here reflect my research interests and biases, and I’ve certainly overlooked areas that others consider vital. This post is pretty long, so I've split it into three parts, with parts II and III to be posted in the next couple of weeks.

Drugs 144
article thumbnail

CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis

Drug Discovery World

Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in B cell-driven autoimmune diseases. “This approval is a critically necessary step that paves the way to enrol patients with treatment-refractory progressive MS for whom there are no currently available

Therapies 312
article thumbnail

What do volunteers for research studies do after finding a trial?

Antidote

For many people, participating in a research study presents an interesting opportunity with many benefits to volunteering. While there are many types of clinical research, all with distinct goals and timelines, trial volunteers will follow a similar path when taking part. Read on to learn more about the process.

Trials 119